PureTech Health plc (PRTC)

Market Cap	505.61M
Revenue (ttm)	15.62M
Net Income (ttm)	-50.35M
Shares Out	27.28M
EPS (ttm)	-1.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	546
Open	18.12
Previous Close	18.38
Day's Range	17.08 - 18.12
52-Week Range	17.08 - 38.51
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2023

About PRTC

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Ms. Daphne Zohar
• Employees: 111
• Stock Exchange: NASDAQ
• Ticker Symbol: PRTC

Financial Performance

In 2022, PRTC's revenue was $15.62 million, a decrease of -10.18% compared to the previous year's $17.39 million. Losses were -$50.35 million, -16.85% less than in 2021.